Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Long noncoding RNA BCYRN1 promotes cardioprotection by enhancing human and murine regulatory T cell dynamics
Ke Liao, Jiayi Yu, Akbarshakh Akhmerov, Zahra Mohammadigoldar, Liang Li, Weixin Liu, Natasha Anders, Ahmed G.E. Ibrahim, Eduardo Marbán
Ke Liao, Jiayi Yu, Akbarshakh Akhmerov, Zahra Mohammadigoldar, Liang Li, Weixin Liu, Natasha Anders, Ahmed G.E. Ibrahim, Eduardo Marbán
View: Text | PDF
Research Article Cardiology

Long noncoding RNA BCYRN1 promotes cardioprotection by enhancing human and murine regulatory T cell dynamics

  • Text
  • PDF
Abstract

Regulatory T cells (Tregs) modulate immune responses and attenuate inflammation. Extracellular vesicles from human cardiosphere-derived cells (CDC-EVs) enhance Treg proliferation and IL-10 production, but the mechanisms remain unclear. Here, we focused on BCYRN1, a long noncoding RNA (lncRNA) highly abundant in CDC-EVs, and its role in Treg function. BCYRN1 acts as a “microRNA sponge,” inhibiting miR-138, miR-150, and miR-98. Suppression of these miRs leads to increased Treg proliferation via ATG7-dependent autophagy, CCR6-dependent Treg migration, and enhanced Treg IL-10 production. In a mouse model of myocardial infarction, CDC-EVs, particularly those overexpressing BCYRN1, were cardioprotective, reducing infarct size and troponin I levels even when administered after reperfusion. Underlying the cardioprotection, we verified that CDC-EVs overexpressing BCYRN1 increased cardiac Treg infiltration, proliferation, and IL-10 production in vivo. These salutary effects were negated when BCYRN1 levels were reduced in CDC-EVs or when Tregs were depleted systemically. Thus, we have identified BCYRN1 as a booster of Treg number and bioactivity, rationalizing its cardioprotective efficacy. While we studied BCYRN1 overexpression in the context of ischemic injury here, the same approach merits testing in other disease processes (e.g., autoimmunity or transplant rejection) where increased Treg activity is a recognized therapeutic goal.

Authors

Ke Liao, Jiayi Yu, Akbarshakh Akhmerov, Zahra Mohammadigoldar, Liang Li, Weixin Liu, Natasha Anders, Ahmed G.E. Ibrahim, Eduardo Marbán

×

Figure 7

Therapeutic efficacy of CDC-EVs and CDC-EV-BCYRN1 in a mouse myocardial infarction model — the role of Tregs.

Options: View larger image (or click on image) Download as PowerPoint
Therapeutic efficacy of CDC-EVs and CDC-EV-BCYRN1 in a mouse myocardial ...
(A) Schematic representation of in vivo myocardial infarction (MI) protocol. (B) Representative flow cytometry plots and pooled data of the CD4+Foxp3+, CD4+Foxp3+IL-10+, and CD4+Foxp3+Brdu+ populations in hearts from animals infused with CDC-EVs, CDC-EVs overexpressing BCYRN1 (CDC-EV-BCYRN1), and IMDM (vehicle) (n = 5 mice per group). (C) Pooled data for percentage of infarct mass (n = 5 mice per group) and representative images of TTC-stained hearts from CDC-EV–, CDC-EV-BCYRN1–, and vehicle-injected animals 72 hours after MI. (D) Plasma cTnI values from CDC-EVs, CDC-EV-BCYRN1– and vehicle-injected animals (n = 5/group) 24 hours after MI. (E) Pooled data for percentage of infarct mass (n = 5/group) of TTC-stained hearts from CDC-EV–, BCYRN1-depleted CDC-EV–, and vehicle-injected animals 72 hours after MI. (F) Plasma cTnI values from CDC-EV–, BCYRN1-depleted CDC-EV–, and vehicle-injected animals (n = 5/group) 24 hours after MI. (G) Echocardiographic analysis of left ventricular ejection fraction (EF) on days 0 (baseline before MI), 7, 14, and 21 after MI with indicated treatment (n = 5/group). (H) Schematic of Treg depletion and in vivo ischemia/reperfusion (I/R) protocol. Mice were injected twice with anti-CD25 antibody (100 μg/mouse/injection i.p.), or isotype control daily for 2 days before I/R. On day 3, TTC assay was used to assess infarct size (n = 5/group). (I) Representative plots showing the percentage of CD25+FoxP3+ in CD4+ T cells (Q2 quadrant). (J) Quantitative measurements of the percentage of infarct mass (n = 5/group) from CDC-EV– or CDC-EV-BCYRN1–injected animals (WT/Treg depletion) at 72 hours after I/R injury. One-way ANOVA followed by Bonferroni’s post hoc test was used to determine the statistical significance among multiple groups. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 versus control group. #P < 0.05 versus CDC-EVs group.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts